On July 21, GSK fell 3.02% in regular trading, trading at $50.17/share, with turnover of $217 million. The decline follows the company's announcement that it will discontinue development of camlipixant for refractory chronic cough.

Camlipixant, a highly selective P2X3 receptor antagonist, was the core asset of GSK's $2 billion all-cash acquisition of Bellus Health. Phase 3 clinical data showed the 50 mg twice-daily dose significantly reduced 24-hour cough frequency versus placebo in the CALM-1 trial but failed to reach statistical significance in CALM-2. The 25 mg dose failed to meet the primary endpoint in both trials. GSK cited limited efficacy as the basis for discontinuation, though the Phase 2b BALANCE trial in irritable bowel syndrome will continue.

The termination of this core respiratory pipeline asset materially weakens the company's mid-to-long-term growth outlook in the respiratory segment, raising concerns over the return on the acquisition investment. The irritable bowel syndrome indication offers a relatively limited market opportunity, insufficient to fully offset the valuation pressure from the chronic cough program failure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)